Sergey Orlov

5.4k total citations · 1 hit paper
149 papers, 2.0k citations indexed

About

Sergey Orlov is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sergey Orlov has authored 149 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Pulmonary and Respiratory Medicine, 64 papers in Oncology and 46 papers in Molecular Biology. Recurrent topics in Sergey Orlov's work include Lung Cancer Treatments and Mutations (65 papers), Lung Cancer Research Studies (35 papers) and Lung Cancer Diagnosis and Treatment (24 papers). Sergey Orlov is often cited by papers focused on Lung Cancer Treatments and Mutations (65 papers), Lung Cancer Research Studies (35 papers) and Lung Cancer Diagnosis and Treatment (24 papers). Sergey Orlov collaborates with scholars based in Russia, United States and South Korea. Sergey Orlov's co-authors include Dizhe Eb, Perevozchikov Ap, Vladimir S. Shavva, Denis A. Mogilenko, Wu‐Chou Su, Lecia V. Sequist, James Chih‐Hsin Yang, S. V. Burov, Ji‐Youn Han and Anders Mellemgaard and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sergey Orlov

144 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Lecia V. Sequist, Byoung Chul Cho et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sergey Orlov Russia	21	1.0k	867	804	293	276	149	2.0k
Yoshihisa Kobayashi Japan	30	1.7k 1.6×	1.0k 1.2×	660 0.8×	331 1.1×	257 0.9×	87	2.5k
Margret Rave‐Fränk Germany	25	395 0.4×	665 0.8×	732 0.9×	343 1.2×	346 1.3×	89	1.9k
Takefumi Ohga Japan	25	594 0.6×	791 0.9×	1.4k 1.7×	214 0.7×	570 2.1×	67	2.4k
Lianhai Zhang China	31	1.1k 1.1×	765 0.9×	1.1k 1.4×	554 1.9×	665 2.4×	122	2.7k
Myoung Jae Kang South Korea	23	449 0.4×	684 0.8×	768 1.0×	312 1.1×	187 0.7×	60	1.9k
Ario Takeuchi Japan	24	913 0.9×	512 0.6×	765 1.0×	415 1.4×	313 1.1×	114	1.9k
Hitoshi Kusaba Japan	24	387 0.4×	946 1.1×	772 1.0×	206 0.7×	249 0.9×	112	1.8k
Tomoyuki Nagai Japan	24	409 0.4×	528 0.6×	599 0.7×	260 0.9×	325 1.2×	95	1.7k
Carsten Grüllich Germany	25	479 0.5×	493 0.6×	557 0.7×	188 0.6×	213 0.8×	90	1.5k
Stephan Macher‐Goeppinger Germany	28	527 0.5×	436 0.5×	1.1k 1.4×	448 1.5×	358 1.3×	59	2.1k

Countries citing papers authored by Sergey Orlov

Since Specialization

Citations

This map shows the geographic impact of Sergey Orlov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergey Orlov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergey Orlov more than expected).

Fields of papers citing papers by Sergey Orlov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergey Orlov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergey Orlov. The network helps show where Sergey Orlov may publish in the future.

Co-authorship network of co-authors of Sergey Orlov

This figure shows the co-authorship network connecting the top 25 collaborators of Sergey Orlov. A scholar is included among the top collaborators of Sergey Orlov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergey Orlov. Sergey Orlov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garassino, Marina Chiara, Yong He, Myung‐Ju Ahn, et al.. (2025). Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung Cancer. 202. 108417–108417.

Vaishampayan, Ulka N., Robert Dreicer, Elisabeth I. Heath, et al.. (2024). A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer. European Journal of Cancer. 202. 114007–114007. 3 indexed citations

Куликов, А. Н., et al.. (2023). Cardioprotective Effect of Soy Protein on a High-Salt Diet in Cynomolgus Monkeys. Journal of Evolutionary Biochemistry and Physiology. 59(3). 969–981. 1 indexed citations

Куликов, А. Н., et al.. (2023). Cardioprotective Effect of Soy Protein on a High-Salt Diet in Cynomolgus Monkeys. Российский физиологический журнал им И М Сеченова. 109(6). 771–787.

Malashicheva, Anna, et al.. (2022). Adiponectin in normal and atherosclerotic intima of human aorta. Russian Journal of Archive of Pathology. 84(6). 16–16. 1 indexed citations

Orlov, Sergey, Aglaya G. Iyevleva, Е. А. Филиппова, et al.. (2021). Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study. Translational Oncology. 14(8). 101121–101121. 7 indexed citations

Shavva, Vladimir S., et al.. (2020). Effect of the insulin on the apolipoprotein a-i gene expression in human macrophages. Medical academic journal. 20(1). 65–74. 1 indexed citations

Shavva, Vladimir S., et al.. (2019). Hypoxia as a Factor Involved in the Regulation of the apoA-1, ABCA1, and Complement C3 Gene Expression in Human Macrophages. Biochemistry (Moscow). 84(5). 529–539. 17 indexed citations

Tanashyan, M. М., et al.. (2017). Metabolic syndrome and ischemic stroke. SHILAP Revista de lepidopterología. 3 indexed citations

10.

Castro, Gilberto de, Daniel Shao-Weng Tan, Lucio Crinò, et al.. (2017). PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). Journal of Thoracic Oncology. 12(1). S7–S7. 8 indexed citations

11.

Shavva, Vladimir S., et al.. (2016). PPARγ Represses Apolipoprotein A‐I Gene but Impedes TNFα‐Mediated ApoA‐I Downregulation in HepG2 Cells. Journal of Cellular Biochemistry. 117(9). 2010–2022. 14 indexed citations

12.

Fein, Luis, Yi‐Long Wu, Lecia V. Sequist, et al.. (2016). P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6. Journal of Thoracic Oncology. 11(10). S202–S203. 4 indexed citations

13.

Tanashyan, M. М., et al.. (2014). Hemorheology and hemostasis in stroke patients with type 2 diabetes and metabolic syndrome. SHILAP Revista de lepidopterología. 8(3). 1 indexed citations

14.

Orlov, Sergey, et al.. (2013). [Cerebrovascular diseases and metabolic syndrome].. SHILAP Revista de lepidopterología. 85(10). 34–42. 2 indexed citations

15.

Glisson, Bonnie S., Andrzej Każarnowicz, Kristiaan Nackaerts, et al.. (2013). A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC). Journal of Thoracic Oncology. 8. 4 indexed citations

16.

Tanashyan, M. М., et al.. (2010). Chronic cerebrovascular diseases, metabolic syndrome, and the hemorrheological and hemostatic systems. SHILAP Revista de lepidopterología. 1 indexed citations

17.

Tanashyan, M. М., et al.. (2009). Metabolic syndrome and cerebrovascular disorders. SHILAP Revista de lepidopterología. 3(3). 1 indexed citations

18.

Orlov, Sergey, et al.. (2009). [The role of ZF5 and CGGBP-20 transcription factors in expression regulation of human FMR1 gene responsible for X-fragile syndrome].. PubMed. 51(12). 1005–12. 3 indexed citations

19.

Mogilenko, Denis A., et al.. (2008). Ap1-like Cis elements in the 5′-regulatory region of the human apolipoprotein A-I gene. Molecular Biology. 42(2). 261–269. 8 indexed citations

20.

Eb, Dizhe, et al.. (2001). Receptor-Mediated Transfer of DNA–Galactosylated Poly-L-lysine Complexes into Mammalian Cells in vitro and in vivo. Biochemistry (Moscow). 66(1). 55–61. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact